* Positive Feedback Received: An International Preliminary Report on
Patentability (IPRP) indicates promising prospects for obtaining granted
patents and protecting the invention
* Unique Attributes and Inventiveness: The feedback highlights the distinct
and inventive nature of all relevant claims in the application,
distinguishing the invention in the field of personalized cancer vaccines
* Strengthened Position: The patentability report reinforces Evaxion's strong
stance in the personalized cancer vaccines field and underlines the
Company's innovative approach
COPENHAGEN, Denmark, June 26, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S
(NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company
specializing in developing AI-Immunology(TM) powered vaccines, receives positive
feedback on its recent patent application for a new type of personalized vaccine
targets, underscoring its novelty and inventiveness.
The patent application PCT/EP2022/086444 discloses a method for identifying a
novel category of tumor vaccine targets derived from Endogenous Retroviruses
(ERVs) using Evaxion's core platform AI-Immunology(TM). With this invention,
Evaxion has tapped into a new source of cancer-specific targets, allowing the
expansion of its personalized vaccines into a broader population of cancer
patients.
"We are thrilled with the recent positive feedback provided in the patentability
report, confirming novelty and inventive step for all relevant claims in our
personalized ERV-based vaccine. This endorsement from the World Intellectual
Property Organization underscores Evaxion's commitment to advancements in cancer
treatment through innovation and reinforces our position at the forefront of the
personalized cancer vaccine field. Establishing the strongest possible
intellectual property portfolio around our inventions is an important element in
our multi-partner strategy. We remain committed to advancing our AI-Immunology(TM)
platform and bringing cutting-edge solutions to patients with high unmet medical
needs," said Christian Kanstrup, CEO at Evaxion.
About ERVs
ERVs are remnants of ancient viruses lying dormant in our genome. ERVs are often
overexpressed in cancer but not in healthy tissue, making them visible to the
immune system and hence promising targets for cancer vaccines. AI-Immunology(TM) is
crucial in allowing the identification of therapeutically relevant ERV tumor
antigens from genomic patient tumor data.
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform,
AI-Immunology(TM). Evaxion's proprietary and scalable AI prediction models harness
the power of artificial intelligence to decode the human immune system and
develop novel immunotherapies for cancer, bacterial diseases, and viral
infections. Based upon AI-Immunology(TM), Evaxion has developed a clinical-stage
oncology pipeline of novel personalized vaccines and a preclinical infectious
disease pipeline in bacterial and viral diseases with high unmet medical needs.
Evaxion is committed to transforming patients' lives by providing innovative and
targeted treatment options. For more information about Evaxion and its
groundbreaking AI-Immunology(TM) platform and vaccine pipeline, please visit our
website (https://www.evaxion-biotech.com/).
Forward-Looking Statement
This announcement contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The words "target," "believe,"
"expect," "hope," "aim," "intend," "may," "might," "anticipate," "contemplate,"
"continue," "estimate," "plan," "potential," "predict," "project," "will," "can
have," "likely," "should," "would," "could," and other words and terms of
similar meaning identify forward-looking statements. Actual results may differ
materially from those indicated by such forward-looking statements as a result
of various factors, including, but not limited to, risks related to: our
financial condition and need for additional capital; our development work; cost
and success of our product development activities and preclinical and clinical
trials; commercializing any approved pharmaceutical product developed using our
AI platform technology, including the rate and degree of market acceptance of
our product candidates; our dependence on third parties including for conduct of
clinical testing and product manufacture; our inability to enter into
partnerships; government regulation; protection of our intellectual property
rights; employee matters and managing growth; our ADSs and ordinary shares, the
impact of international economic, political, legal, compliance, social and
business factors, including inflation, and the effects on our business from the
worldwide ongoing COVID-19 pandemic and the ongoing conflict in the region
surrounding Ukraine and Russia and the Middle East; and other uncertainties
affecting our business operations and financial condition. For a further
discussion of these risks, please refer to the risk factors included in our most
recent Annual Report on Form 20-F and other filings with the U.S. Securities and
Exchange Commission (SEC), which are available at www.sec.gov
(https://www.globenewswire.com/Tracker?data=3eX-
yULjXHj_fAO4jPRASPaehYEVHM4NmXNAs_0lw5UK0DHjLXk6aKS6LI4PyMob9UvuFpZpGQrWa4b_6WQY
1A==). We do not assume any obligation to update any forward-looking statements
except as required by law.
Â